Asset Details
Do you wish to reserve the book?
Comparative study of clinical grade human tolerogenic dendritic cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparative study of clinical grade human tolerogenic dendritic cells
Do you wish to request the book?
Comparative study of clinical grade human tolerogenic dendritic cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparative study of clinical grade human tolerogenic dendritic cells
2011
Overview
Background
The use of tolerogenic DCs is a promising therapeutic strategy for transplantation and autoimmune disorders. Immunomodulatory DCs are primarily generated from monocytes (MDDCs) for
in vitro
experiments following protocols that fail to fulfil the strict regulatory rules of clinically applicable products. Here, we compared the efficacy of three different tolerance-inducing agents, dexamethasone, rapamycin and vitamin D3, on DC biology using GMP (
Good Manufacturing Practice
) or clinical grade reagents with the aim of defining their use for human cell therapy.
Methods
Tolerogenic MDDCs were generated by adding tolerogenic agents prior to the induction of maturation using TNF-α, IL-β and PGE2. We evaluated the effects of each agent on viability, efficiency of differentiation, phenotype, cytokine secretion and stability, the stimulatory capacity of tol-DCs and the T-cell profiles induced.
Results
Differences relevant to therapeutic applicability were observed with the cellular products that were obtained. VitD3-induced tol-DCs exhibited a slightly reduced viability and yield compared to Dexa-and Rapa-tol-DCs. Phenotypically, while Dexa-and VitD3-tol-DCs were similar to immature DCs, Rapa-tol-DCs were not distinguishable from mature DCs. In addition, only Dexa-and moderately VitD3-tol-DCs exhibited IL-10 production. Interestingly, in all cases, the cytokine secretion profiles of tol-DCs were not modified by a subsequent TLR stimulation with LPS, indicating that all products had stable phenotypes. Functionally, clearly reduced alloantigen T cell proliferation was induced by tol-DCs obtained using any of these agent. Also, total interferon-gamma (IFN-γ) secretion by T cells stimulated with allogeneic tol-DCs was reduced in all three cases, but only T cells co-cultured with Rapa-tol-DCs showed impaired intracellular IFN-γ production. In addition, Rapa-DCs promoted CD4+ CD127 low/negative CD25high and Foxp3+ T cells.
Conclusions
Our results demonstrate contrasting influences of different clinical-grade pharmacological agents on human tol-DC generation. This should be taken into account for decisions on the use of a specific agent for the appropriate cellular therapy in the context of a particular disease.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
Anti-Inflammatory Agents - metabolism
/ Biomedical and Life Sciences
/ Cell Differentiation - drug effects
/ Cell Proliferation - drug effects
/ Cell Survival - drug effects
/ Cholecalciferol - pharmacology
/ Dendritic Cells - drug effects
/ Dendritic Cells - immunology
/ Dexamethasone - pharmacology
/ Forkhead Transcription Factors - metabolism
/ Humans
/ Immune Tolerance - drug effects
/ Immune Tolerance - immunology
/ Interferon-gamma - secretion
/ Interleukin-10 - biosynthesis
/ Lipopolysaccharides - pharmacology
